Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.29
IDXX's Cash to Debt is ranked lower than
83% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. IDXX: 0.29 )
Ranked among companies with meaningful Cash to Debt only.
IDXX' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 9.10 Max: No Debt
Current: 0.29
Equity to Asset -0.05
IDXX's Equity to Asset is ranked lower than
91% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. IDXX: -0.05 )
Ranked among companies with meaningful Equity to Asset only.
IDXX' s Equity to Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.75 Max: 0.87
Current: -0.05
-0.06
0.87
Interest Coverage 9.63
IDXX's Interest Coverage is ranked lower than
64% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.72 vs. IDXX: 9.63 )
Ranked among companies with meaningful Interest Coverage only.
IDXX' s Interest Coverage Range Over the Past 10 Years
Min: 10.26  Med: 58.07 Max: 276.91
Current: 9.63
10.26
276.91
F-Score: 5
Z-Score: 4.99
M-Score: -2.63
WACC vs ROIC
3.70%
27.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.38
IDXX's Operating margin (%) is ranked higher than
88% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. IDXX: 18.38 )
Ranked among companies with meaningful Operating margin (%) only.
IDXX' s Operating margin (%) Range Over the Past 10 Years
Min: 14.76  Med: 18.00 Max: 20.3
Current: 18.38
14.76
20.3
Net-margin (%) 11.70
IDXX's Net-margin (%) is ranked higher than
85% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.99 vs. IDXX: 11.70 )
Ranked among companies with meaningful Net-margin (%) only.
IDXX' s Net-margin (%) Range Over the Past 10 Years
Min: 10.19  Med: 12.46 Max: 13.78
Current: 11.7
10.19
13.78
ROA (%) 13.05
IDXX's ROA (%) is ranked higher than
93% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.96 vs. IDXX: 13.05 )
Ranked among companies with meaningful ROA (%) only.
IDXX' s ROA (%) Range Over the Past 10 Years
Min: 13.44  Med: 15.96 Max: 17.84
Current: 13.05
13.44
17.84
ROC (Joel Greenblatt) (%) 56.76
IDXX's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. IDXX: 56.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IDXX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 53.83  Med: 62.77 Max: 85.38
Current: 56.76
53.83
85.38
Revenue Growth (3Y)(%) 14.10
IDXX's Revenue Growth (3Y)(%) is ranked higher than
80% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. IDXX: 14.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IDXX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.4  Med: 11.20 Max: 23.1
Current: 14.1
8.4
23.1
EBITDA Growth (3Y)(%) 12.00
IDXX's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. IDXX: 12.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IDXX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.3  Med: 15.10 Max: 96.9
Current: 12
3.3
96.9
EPS Growth (3Y)(%) 8.90
IDXX's EPS Growth (3Y)(%) is ranked higher than
63% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.60 vs. IDXX: 8.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IDXX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.5  Med: 16.10 Max: 26.2
Current: 8.9
-0.5
26.2
» IDXX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

IDXX Guru Trades in Q1 2015

Steven Cohen 2,000 sh (New)
Chris Davis 355,648 sh (+1.10%)
Mairs and Power 2,199 sh (unchged)
Paul Tudor Jones Sold Out
Ron Baron 3,614,135 sh (-0.24%)
Chuck Royce 957,011 sh (-3.80%)
Ruane Cunniff 4,078,152 sh (-8.32%)
Jim Simons 291,952 sh (-8.41%)
RS Investment Management 171,342 sh (-15.01%)
John Hussman 29,000 sh (-20.11%)
Jeremy Grantham 29,400 sh (-29.67%)
» More
Q2 2015

IDXX Guru Trades in Q2 2015

Ray Dalio 4,226 sh (New)
George Soros 17,974 sh (New)
Paul Tudor Jones 10,730 sh (New)
Chris Davis 733,629 sh (+106.28%)
Ron Baron 7,171,279 sh (+98.42%)
Mairs and Power 3,998 sh (+81.81%)
Chuck Royce 1,616,622 sh (+68.92%)
Jeremy Grantham 58,800 sh (unchged)
Steven Cohen Sold Out
John Hussman Sold Out
Ruane Cunniff 8,083,238 sh (-0.90%)
RS Investment Management 329,044 sh (-3.98%)
Jim Simons 254,804 sh (-12.72%)
» More
Q3 2015

IDXX Guru Trades in Q3 2015

Ray Dalio 7,826 sh (+85.19%)
RS Investment Management 370,574 sh (+12.62%)
Chuck Royce 1,770,922 sh (+9.54%)
Ruane Cunniff 8,167,274 sh (+1.04%)
Mairs and Power 3,998 sh (unchged)
Jeremy Grantham Sold Out
Paul Tudor Jones 10,711 sh (-0.18%)
Ron Baron 7,061,667 sh (-1.53%)
Chris Davis 623,573 sh (-15.00%)
George Soros 6,800 sh (-62.17%)
Jim Simons 33,100 sh (-87.01%)
» More
Q4 2015

IDXX Guru Trades in Q4 2015

Jim Simons 127,700 sh (+285.80%)
Mairs and Power 3,998 sh (unchged)
Ray Dalio Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
Ruane Cunniff 8,027,368 sh (-1.71%)
Ron Baron 6,891,469 sh (-2.41%)
Chuck Royce 1,207,722 sh (-31.80%)
Chris Davis 264,392 sh (-57.60%)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories Inc. - Apr 26, 2016

Shares IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported healthy financial results. We believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 50% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories grew at more than twice the rate of its main competitor. We also observed rising productivity of its field salesforce, and a rebound in its rapid assay products. We believe that these trends, coupled with a number of new tests that should emerge from its meaningful research and development effort, will drive increased organic revenue and earnings growth during the next few years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jan 14, 2016

Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a leader in veterinary diagnostics. The company is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. It has had much success placing its proprietary testing instrument in clinics, and has a deep pipeline of tests and products. Its razor/razorblade model results in high retention rates and incremental margins. IDEXX is transitioning to all-direct distribution, which we expect will further enhance margins and future growth.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Nov 04, 2015

Shares of veterinary diagnostics manufacturer IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to the third quarter performance. The company reported strong second quarter results that demonstrated share gains in instruments and reference labs, and assuaged concerns regarding its competitive position in rapid assays. Catalyst placements grew 44% in the quarter, driven by the launch of CatalystOne in the U.S. and Europe. Premium hematology placements grew 30% in the third quarter, a meaningful increase from 14% in the second quarter. Reference lab results were also strong, growing 12.1% in the third quarter. (Neal Rosenberg)



From Baron Funds' Baron Partners Fund shareholder letter for Q3 2015.



Check out Ron Baron latest stock trades

Sequoia Fund Comments on Idexx - Aug 28, 2015

Arman Kline:



The company had a wonderful 2014. It made a big decision to go to direct distribution. Historically, Idexx (NASDAQ:IDXX) distributed the consumables for its instruments and its rapid assay tests for companion animals through a network of distributors in the US. Overseas it was a little bit more direct. It made a decision to go direct here, and the reason it made that decision is that it felt as the market leader with a dominant market share introducing new technology, new products, it needed a sales force that could encourage the adoption of those products more than it needed the help of distributors to penetrate the market. We think that management made the right decision.



Earlier this year, you may have noticed in the first quarter, Idexx had a little bit of a hiccup as a result of that move to direct distribution. A competitor came out with a lower priced product and distributors picked it up because Idexx was no longer selling through them. The competitor was very aggressive, and, as the CEO of Idexx said, there is now a rapid assay price war going on in the industry. The business is still growing very nicely, but the stock was priced for perfection — last year it was trading for a high 30s multiple of forward earnings. Most of you have probably noticed we have sold down our position as a result of that valuation. We are still large shareholders. We still believe in the business. We think it is unique. We think it has a long runway. We think it will continue to dominate that space. We remain excited about the future there and believe in its direct distribution model. Do you want to add anything, Greg?



Greg Steinmetz:



Idexx is responsible for at least 75% if not more of all of the R&D spending in veterinary diagnostics. It can earn a nice return on that because this megatrend of the humanization of pets is showing no signs of stopping. People will spend anything on their animal if the veterinarian gives them a credible reason why they should. And it is a lot more than just rich people. It is a broad swath of pet owners. Idexx, to its credit, is a great believer in veterinary diagnostics. Management sees it as a very long-lived opportunity. It has really been paying off. Despite the issue with rapid assay this year, we are still going to get 10% organic growth. International is going gangbusters, and there the humanization of pets is just getting started. Even in China — where they are boiling Tibetan mastiffs, if you read the story in the Times two weeks ago — people are starting to treat animals more like humans. It is an opportunity that Idexx is going to benefit a great deal from.



From Ruane, Cunniff & Goldfarb Investor Day 2015 Transcript Part II - Sequoia Fund.



Check out Ruane Cunniff latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Aug 18, 2015

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), a leader in veterinary diagnostics, detracted from performance after outperforming meaningfully during recent periods. We attribute a portion of the stock’s decline to greater-than-expected foreign exchange headwinds. Separately, the company noted increased competition and lower prices in a sub-segment of its product portfolio, which we estimate accounts for just 3% of total revenue. We believe this enhanced competition stems from the company’s recent transition to a direct sales strategy in the U.S., and we are optimistic that management will successfully react with pricing programs to better serve these customers in the future. We expect accelerating organic revenue growth over the next several years, driven by productivity benefits from its new domestic sales strategy, additional products, and ongoing success in international markets. We believe that faster top line growth should lead to accelerated margin expansion, creating a virtuous cycle of earnings growth, reinvestment, and returns of capital to shareholders.



From Baron Funds' second quarter commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc - Mar 23, 2015

Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose in the fourth quarter on better-than-expected earnings and progress on moving to a direct distribution model in the U.S. IDEXX’s fundamentals continue to improve, with organic growth in its core business reaching 12% in the most recently reported quarter. We believe organic revenue growth at current levels is sustainable due to recent innovations in IDEXX’s portfolio of diagnostic products, instruments, data management tools, and geographic expansion. (Rebecca Ellin)

From Ron Baron (Trades, Portfolio)'s Baron Partners Fund Fourth Quarter 2014 Commentary.

Check out Ron Baron latest stock trades

Top Ranked Articles about IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Shares IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported healthy financial results. We believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 50% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories grew at more than twice the rate of its main competitor. We also observed rising productivity of its field salesforce, and a rebound in its rapid assay products. We believe that these trends, coupled with a number of new tests that should emerge from its meaningful research and development effort, will drive increased organic revenue and earnings growth during the next few years. Read more...
Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a leader in veterinary diagnostics. The company is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. It has had much success placing its proprietary testing instrument in clinics, and has a deep pipeline of tests and products. Its razor/razorblade model results in high retention rates and incremental margins. IDEXX is transitioning to all-direct distribution, which we expect will further enhance margins and future growth. Read more...
Baron Funds Comments on IDEXX Laboratories Guru stock highlight.
Shares of veterinary diagnostics manufacturer IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to the third quarter performance. The company reported strong second quarter results that demonstrated share gains in instruments and reference labs, and assuaged concerns regarding its competitive position in rapid assays. Catalyst placements grew 44% in the quarter, driven by the launch of CatalystOne in the U.S. and Europe. Premium hematology placements grew 30% in the third quarter, a meaningful increase from 14% in the second quarter. Reference lab results were also strong, growing 12.1% in the third quarter. (Neal Rosenberg) Read more...
Sequoia Fund Comments on Idexx Guru stock highlight
Arman Kline: Read more...
Baron Funds Comments on IDEXX Laboratories Inc.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), a leader in veterinary diagnostics, detracted from performance after outperforming meaningfully during recent periods. We attribute a portion of the stock’s decline to greater-than-expected foreign exchange headwinds. Separately, the company noted increased competition and lower prices in a sub-segment of its product portfolio, which we estimate accounts for just 3% of total revenue. We believe this enhanced competition stems from the company’s recent transition to a direct sales strategy in the U.S., and we are optimistic that management will successfully react with pricing programs to better serve these customers in the future. We expect accelerating organic revenue growth over the next several years, driven by productivity benefits from its new domestic sales strategy, additional products, and ongoing success in international markets. We believe that faster top line growth should lead to accelerated margin expansion, creating a virtuous cycle of earnings growth, reinvestment, and returns of capital to shareholders. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 41.61
IDXX's P/E(ttm) is ranked lower than
67% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.31 vs. IDXX: 41.61 )
Ranked among companies with meaningful P/E(ttm) only.
IDXX' s P/E(ttm) Range Over the Past 10 Years
Min: 15.2  Med: 30.59 Max: 46.85
Current: 41.61
15.2
46.85
Forward P/E 35.71
IDXX's Forward P/E is ranked lower than
86% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.92 vs. IDXX: 35.71 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 41.61
IDXX's PE(NRI) is ranked lower than
68% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.12 vs. IDXX: 41.61 )
Ranked among companies with meaningful PE(NRI) only.
IDXX' s PE(NRI) Range Over the Past 10 Years
Min: 15.02  Med: 30.54 Max: 46.66
Current: 41.61
15.02
46.66
Price/Owner Earnings (ttm) 41.71
IDXX's Price/Owner Earnings (ttm) is ranked lower than
74% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.08 vs. IDXX: 41.71 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
IDXX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 21.36  Med: 32.21 Max: 73.8
Current: 41.71
21.36
73.8
P/S 4.92
IDXX's P/S is ranked lower than
66% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. IDXX: 4.92 )
Ranked among companies with meaningful P/S only.
IDXX' s P/S Range Over the Past 10 Years
Min: 1.75  Med: 3.95 Max: 5.77
Current: 4.92
1.75
5.77
PFCF 46.71
IDXX's PFCF is ranked lower than
78% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.30 vs. IDXX: 46.71 )
Ranked among companies with meaningful PFCF only.
IDXX' s PFCF Range Over the Past 10 Years
Min: 13.03  Med: 34.01 Max: 183.41
Current: 46.71
13.03
183.41
POCF 31.65
IDXX's POCF is ranked lower than
77% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.11 vs. IDXX: 31.65 )
Ranked among companies with meaningful POCF only.
IDXX' s POCF Range Over the Past 10 Years
Min: 11.44  Med: 23.95 Max: 44.83
Current: 31.65
11.44
44.83
EV-to-EBIT 28.01
IDXX's EV-to-EBIT is ranked lower than
69% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.72 vs. IDXX: 28.01 )
Ranked among companies with meaningful EV-to-EBIT only.
IDXX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.5  Med: 20.80 Max: 34.6
Current: 28.01
10.5
34.6
EV-to-EBITDA 22.65
IDXX's EV-to-EBITDA is ranked lower than
74% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.76 vs. IDXX: 22.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDXX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.3  Med: 17.00 Max: 28.2
Current: 22.65
8.3
28.2
PEG 3.40
IDXX's PEG is ranked lower than
61% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. IDXX: 3.40 )
Ranked among companies with meaningful PEG only.
IDXX' s PEG Range Over the Past 10 Years
Min: 0.78  Med: 2.08 Max: 3.84
Current: 3.4
0.78
3.84
Shiller P/E 60.49
IDXX's Shiller P/E is ranked lower than
87% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.90 vs. IDXX: 60.49 )
Ranked among companies with meaningful Shiller P/E only.
IDXX' s Shiller P/E Range Over the Past 10 Years
Min: 26.11  Med: 50.55 Max: 80.82
Current: 60.49
26.11
80.82
Current Ratio 0.92
IDXX's Current Ratio is ranked lower than
86% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. IDXX: 0.92 )
Ranked among companies with meaningful Current Ratio only.
IDXX' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.58 Max: 6
Current: 0.92
0.92
6
Quick Ratio 0.71
IDXX's Quick Ratio is ranked lower than
87% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. IDXX: 0.71 )
Ranked among companies with meaningful Quick Ratio only.
IDXX' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.83 Max: 5.14
Current: 0.71
0.71
5.14
Days Inventory 91.70
IDXX's Days Inventory is ranked higher than
52% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. IDXX: 91.70 )
Ranked among companies with meaningful Days Inventory only.
IDXX' s Days Inventory Range Over the Past 10 Years
Min: 77.45  Med: 82.31 Max: 89.55
Current: 91.7
77.45
89.55
Days Sales Outstanding 47.29
IDXX's Days Sales Outstanding is ranked higher than
75% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.42 vs. IDXX: 47.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDXX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.43  Med: 40.46 Max: 42.91
Current: 47.29
37.43
42.91
Days Payable 26.06
IDXX's Days Payable is ranked lower than
80% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.01 vs. IDXX: 26.06 )
Ranked among companies with meaningful Days Payable only.
IDXX' s Days Payable Range Over the Past 10 Years
Min: 13.82  Med: 22.50 Max: 27
Current: 26.06
13.82
27

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.51
IDXX's Price/Projected FCF is ranked lower than
72% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. IDXX: 3.51 )
Ranked among companies with meaningful Price/Projected FCF only.
IDXX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.14  Med: 2.40 Max: 3.98
Current: 3.51
1.14
3.98
Price/DCF (Earnings Based) 2.23
IDXX's Price/DCF (Earnings Based) is ranked lower than
71% of the 14 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. IDXX: 2.23 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.24
IDXX's Price/Median PS Value is ranked lower than
71% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. IDXX: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
IDXX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.46  Med: 0.87 Max: 1.82
Current: 1.24
0.46
1.82
Price/Peter Lynch Fair Value 3.74
IDXX's Price/Peter Lynch Fair Value is ranked lower than
88% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. IDXX: 3.74 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
IDXX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.88  Med: 1.76 Max: 3.68
Current: 3.74
0.88
3.68
Earnings Yield (Greenblatt) (%) 3.57
IDXX's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. IDXX: 3.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IDXX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 4.80 Max: 9.5
Current: 3.57
2.9
9.5
Forward Rate of Return (Yacktman) (%) 12.84
IDXX's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.85 vs. IDXX: 12.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IDXX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.8  Med: 17.40 Max: 22.4
Current: 12.84
12.8
22.4

More Statistics

Revenue(Mil) $1602
EPS $ 2.05
Beta0.28
Short Percentage of Float7.63%
52-Week Range $61.58 - 86.61
Shares Outstanding(Mil)89.53

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 1,739 1,858
EPS($) 2.18 2.41
EPS without NRI($) 2.18 2.41

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:TMO, NYSE:A, TSE:6869, NYSE:LH, NYSE:DGX, XSWX:LONN » details
Traded in other countries:IX1.Germany,
IDEXX Laboratories Inc was incorporated in 1983. The Company develops, manufactures and distributes products and provides services for the veterinary, bioresearch, water, livestock, poultry and dairy markets. It also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. The Company operates through three segments: CAG, Water, and LPD. CAG develops, designs, manufactures and distributes products and performs services for veterinarians and the bioresearch market related to diagnostics and information management. Water develops, designs, manufactures and distributes a products used in the detection of various microbiological parameters in water. LPD develops, designs, manufactures and distributes diagnostic tests and related instrumentation that are used to manage the health status of livestock and poultry, to improve bovine reproductive efficiency, and to ensure the quality and safety of milk and food. OPTI Medical develops, designs, manufactures and distributes point-of-care electrolyte and blood gas analyzers and related consumable products for the human medical diagnostics market. It competes with many companies ranging from large human pharmaceutical and medical diagnostics companies to small businesses focused on animal health. Its companion animal veterinary diagnostic products and services compete with both reference laboratory service and in-clinic product providers. The Company's trademarks include 4Dx, Catalyst Dx, Catalyst One, Coag Dx, Colilert, Colisure, Cornerstone, DVMAX, Enterolert, Feline Triple, Filta-Max, Filta-Max xpress, IDEXX I-Vision CR, IDEXX I-Vision DR, IDEXX I-Vision Mobile, IDEXX ImageBank, IDEXX-PACS, IDEXX VetLab, IDEXX VPM, LaserCyte, LaserCyte Dx, Navigator, OPTI, OPTI LION, PetChek, PetDetect, Pet Health Network, Practice Profile, ProCyte Dx, Pseudalert, Quanti-Tray, SimPlate, SmartService, SNAP, SNAPduo, SNAP Pro, SNAP cPL, SNAP fPL, SNAPshot Dx, VetAutoread, VetConnect, VetLab UA, VetLINK, VetLyte, VetStat, VetTest and VetVault. Many of its products are subject to comprehensive regulation by U.S. and foreign regulatory agencies that relate to, among other things, product approvals, manufacturing, distribution, marketing and promotion, labeling, recordkeeping, testing, quality, storage and product disposal.
» More Articles for IDXX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on IDEXX Laboratories Inc. Apr 26 2016 
Baron Asset Fund 1st Quarter Commentary Apr 26 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Jan 14 2016 
Baron Funds Comments on IDEXX Laboratories Nov 04 2015 
Ron Baron's Largest Purchases During Second Quarter Sep 28 2015 
Sequoia Fund Comments on Idexx Aug 28 2015 
Ruane, Cunniff & Goldfarb Investor Day 2015 Transcript Part II Aug 27 2015 
Baron Funds Comments on IDEXX Laboratories Inc. Aug 18 2015 
Baron Funds Spring Newsletter: The Advantages of Mid-Cap Stocks Jun 10 2015 
Distribution: A Potentially Under-appreciated Moat Jun 08 2015 

More From Other Websites
IDEXX LABORATORIES INC /DE Financials May 05 2016
IDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
IDEXX Laboratories (IDXX) Tops Q1 Earnings; Lifts '16 View May 02 2016
Edited Transcript of IDXX earnings conference call or presentation 29-Apr-16 12:30pm GMT Apr 29 2016
IDEXX Laboratories Inc Earnings Call scheduled for 8:30 am ET today Apr 29 2016
Idexx beats Street 1Q forecasts Apr 29 2016
Idexx beats Street 1Q forecasts Apr 29 2016
Q1 2016 IDEXX Laboratories Inc Earnings Release - Before Market Open Apr 29 2016
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 29 2016
IDEXX Laboratories Announces First Quarter Results Apr 29 2016
First Quarter 2016 Earnings Conference Call Apr 28 2016
Why Do Fund Managers Find This Top Medical Device Maker ‘Infectious’? Apr 28 2016
IDEXX Laboratories to Release 2016 First Quarter Financial Results Apr 12 2016
Coverage initiated on IDEXX Labs by CL King Apr 01 2016
IDEXX: Strong Q4 Raises Hope amid Bleak Currency Scenario Mar 15 2016
IDEXX Laboratories to Present at Raymond James Institutional Investors Conference Feb 29 2016
IDEXX LABORATORIES INC /DE Files SEC form 10-K, Annual Report Feb 17 2016
Pets are comforting, but shares of pet-focused companies may not be Feb 15 2016
IDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : February 12, 2016 Feb 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK